Print Options

Font size:

← Back to notecard set|Easy Notecards home page

To print: Ctrl+PPrint as notecards

infectious diseases manifesting in the gastrointestinal tract

1.

dental caries disease table

2.

dental caries causative agent

a polymicrobial mixture of acid-producing bacteria

3.

dental caries mode of transmission

direct contact

4.

dental caries virulence factors

adhesion, acid production

5.

dental caries culture/diagnosis

N/A

6.

dental caries prevention

oral hygiene, fluoride supplementation

7.

dental caries treatment

removal of diseased tooth material

8.

dental caries epidemiological features

globally, 60% to 90% prevalence in school-age children

9.

periodontitis disease table

10.

necrotizing ulcerative gingivitis and periodontitis disease table

11.

periodontitis causative agents

polymicrobial community including some or all of Tannerella forsythia, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and others

12.

periodontitis virulence factors

induction of inflammation, enzymatic destruction of tissues

13.

periodontitis prevention

oral hygiene

14.

periodontitis treatment

removal of plaque and calculus, gum reconstruction, and possibly anti-inflammatory treatments

15.

periodontitis epidemiological features

US: smokers = 11%, nonsmokers = 2%, and internationally: 10% to 15% of adults

16.

NUG or NUP causative agents

polymicrobial community (treponema vincentii, prevotella intermedia, and fuso bacterium species)

17.

NUG or NUP virulence factors

inflammation, invasiveness

18.

NUG or NUP prevention

oral hygiene

19.

NUG or NUP treatment

debridement of damaged tissue, possibly antibiotics

20.

NUG or NUP epidemiological features

N/A

21.

mumps disease table

22.

mumps causative agent

mumps virus (genus paramyxovirus)

23.

mumps mode of transmission

droplet contact

24.

mumps virulence factors

spike-induced syncytium formation

25.

mumps culture/diagnosis

ELISA for Ab; PCR

26.

mumps prevention

MMR live attenuated vaccine

27.

mumps treatment

supportive

28.

mumps epidemiological features

US: fluctuates between a few hundred cases a year and a few thousand; internationally; epidemic peaks every 2 to 5 years

29.

gastritis and gastric ulcers disease table

30.

gastritis causative agents

helicobacter pylori

31.

gastritis mode of transmission

oral-oral or oral-fecal route likely

32.

gastritis virulence factors

adhesins, urease

33.

gastritis culture/diagnosis

direct antigen test on stool, urea breath test

34.

gastritis prevention

none

35.

gastritis treatment

clarithromycin + acid suppression

36.

gastritis epidemiological features

US: infection (not disease) rates at 35% of adults; internationally: infection rates at 50%

37.

acute diarrhea causative agents

salmonella, shigella, shiga toxin-producing E. coli, other E. colie, campylobacter, clostridioides difficile, vibrio cholerae, and non-cholera vibrio species

38.

salmonella disease table

39.

shigella disease table

40.

shiga toxin-producing E. coli disease table

41.

other E. coli disease table

42.

campylobacter disease table

43.

clostridioides difficile disease table

44.

vibrio cholerae disease table

45.

non-cholera vibrio species

46.

salmonella mode of transmission

vehicle (food, beverage), fecal-oral

47.

salmonella virulence factors

adhesions, endotoxin

48.

salmonella culture/diagnosis

stool culture, not usually necessary

49.

salmonella prevention

food hygiene and personal hygiene

50.

salmonella treatment

rehydration; no antibiotic for uncomplicated disease; in complicated disease ciprofloxacin; resistant salmonella is considered a serious threat by the CDC

51.

is fever present with salmonella?

usually

52.

is blood present in the stool with salmonella?

sometimes

53.

salmonella distinctive features

often associated with chickens, reptiles

54.

salmonella epidemiological features

US: +/- 1.2 million cases per year; 20% of all cases require hospitalization; death rate of 0.6%; category b bioterrorism agent

55.

shigella mode of transmission

fecal-oral, direct contact

56.

shigella virulence factors

endotoxin, enterotoxinm and shiga toxins in some strains

57.

shigella culture/diagnosis

stool culture; antigen testing for shiga toxin

58.

shigella prevention

food hygiene and personal hygiene

59.

shigella treatment

azitromycin or ciprofloxacin; drug-resistant shigella is in the CDC's serious threat category

60.

is fever present with shigella?

often

61.

is blood in the stool with shigella?

often

62.

shigella distinctive features

very low in ID50

63.

shigella epidemiological features

US: estimated 450,000 cases per year; internationally: 165 million cases per year; category b bioterrorism agent

64.

shiga toxin-producing E. coli mode of transmission

vehicle (food, beverage), fecal-oral

65.

shiga toxin-producing E.coli virulence factors

shiga toxins; proteins for attachment, secretion, and effacement

66.

shiga toxin-producing culture/diagnosis

stool culture, antigen testing for shiga toxin

67.

shiga-toxin producing E.coli prevention

avoid live E. coli (cook meat and clean vegetables); stay aware of food recalls

68.

shiga-toxin producing E.coli treatment

antibiotics contraindicated, supportive measures

69.

is fever present when shiga-toxin producing E.coli?

often

70.

is blood in the stool with shiga-toxin producing E.coli?

usually

71.

shiga toxin-producing distinctive features

hemolytic uremic syndrome

72.

shiga toxin-producing epidemiological features

internationally: causes HUS in 10% of patients; 25% of HUS patients suffer neurological complications, 50% have chronic renal sequelae; category b bioterrorism agent

73.

other E.coli mode of transmission

vehicle, fecal-oral

74.

other E.coli virulence factors

various: proteins for attachment, secretion, effacement; heat-liable, and/or heat-stable exotoxins; invasiveness

75.

other E.coli culture/diagnosis

stool culture not usually necessary in absence of blood, fever

76.

other E.coli prevention

food and personal hygiene

77.

other E.coli treatment

rehydration, anti-motility agent

78.

other E.coli fever present

sometimes

79.

other E.coli blood in stool

sometimes

80.

other E.coli distinctive features

ETEC, EIEC, EPEC, DAEC, EAEC

81.

campylobacter mode of transmission

vehicle (food, water), fecal-oral

82.

campylobacter virulence factors

adhesins, exotoxin, and induction of autoimmunity

83.

campylobacter culture/diagnosis

stool culture not usually necessary; dark-field microscopy

84.

campylobacter prevention

food and personal hygiene

85.

campylobacter treatment

rehydration; azithromycin in severe cases

86.

campylobacter fever present

usually

87.

campylobacter blood in stool

no

88.

campylobacter distinctive features

guillain-barre syndrome

89.

campylobacter epidemiolgica features

US: 1.3 million cases per year; internationally: 400 million cases per year

90.

clostridioides difficle mode of transmission

endogenous (normal biota)

91.

clostridioides difficle virulence factors

enterotoxins A and B

92.

clostridioides difficle culture/diagnosis

stool culture, PCR, ELISA demonstration of toxins in stool

93.

clostridioides difficle prevention

N/A

94.

clostridioides difficle treatment

metronidazole in mild cases, vancomycin for severe, fecal transplants, resistant strains are in the CDC's urgent threat category

95.

clostridioides difficle fever present

sometimes

96.

clostridioides difficle blood in stool

not usually; mucus prominent

97.

clostridioides difficle distinctive features

associated with disruption of normal biota

98.

clostridioides difficle epidemiologic features

US: 500,000 cases per year

99.

vibrio cholerae mode of transmission

vehicle (water and some foods), fecal-oral

100.

vibrio cholerae virulence factors

cholera toxin

101.

vibrio cholerae culture/diagnosis

clinical diagnosis, microscopic techniques, serological detection of antitoxin

102.

vibrio cholerae prevention

water and food hygiene

103.

vibrio cholerae treatment

rehydration and possibly doxycycline

104.

vibrio cholerae fever present

no

105.

vibrio cholerae blood in stool

no

106.

vibrio cholerae distinctive features

rice-water stools

107.

vibrio cholerae epidemiological features

global estimate: 21,000-143,000 deaths annually; category b bioterrorism agent

108.

non-cholera vibrio species mode of transmission

vehicle (food or natural bodies of water)

109.

non-cholera vibrio species virulence factors

N/A

110.

non-cholera vibrio species culture diagnosis

culture of stool or blood

111.

non-cholera vibrio species prevention

avoiding raw shellfish

112.

non-cholera vibrio species treatment

doxycycline

113.

non-cholera vibrio species fever present

yes

114.

non-cholera vibrio species blood in stoool

no

115.

non-cholera vibrio species distinctive features

sepsis can follow

116.

non-cholera vibrio species epidemiological features

cause: 90% of seafood-related deaths in the US

117.

nonbacterial causes of acute diarrhea

cryptosporidium, rotavirus, norovirus

118.

cryptosporidium mode of transmission

vehicle (water, food), fecal-oral

119.

cryptosporidium virulence factors

intracellular growth

120.

cryptosporidium culture/diagnosis

acid-fast staining, ruling out bacteria

121.

cryptosporidium prevention

water treatment, proper food handling

122.

cryptosporidium treatment

none of nitazoxanide

123.

cryptosporidium fever present

often

124.

cryptosporidium blood in stool

not usually

125.

cryptosporidium distinctive features

resistant to chlorine disinfection

126.

cryptosporidium epidemiological features

US: estimated 748,000 cases per year; 30% seropositive; category b bioterrorism agent

127.

rotavirus mode of transmission

fecal-oral, vehicle, formite

128.

rotavirus virulence factors

N/A

129.

rotavirus culture/diagnosis

rapid antigen test

130.

rotavirus prevention

oral live-virus vaccine

131.

rotavirus treatment

rehydration

132.

rotavirus fever present

often

133.

rotavirus blood in stool

no

134.

rotavirus distinctive features

severe in infants

135.

rotavirus epidemiological features

US: 2-3 million cases per year internationally; 125 million cases of infantile diarrhea annually

136.

norovirus mode of transmission

indirect, vehicle (food), direct contact

137.

norovirus virulence factors

limited immunity to reinfection

138.

norovirus culture/diagnosis

rapid antigen test

139.

norovirus prevention

hygiene

140.

norovirus treatment

rehydration

141.

norovirus fever present

sometimes

142.

norovirus blood in stool

no

143.

norovirus distinctive features

resistant to disinfection

144.

norovirus epidemiological features

US: second most common cause of foodborne illness hospitalizations

145.

are fevers present in acute diarrhea with vomitting?

not usually

146.

is blood in stool present in acute diarrhea with vomitting?

no

147.

acute diarrhea with vomiting causative agents

staphylococcus aureus exotoxin, bacillus cereus exotoxin, clostridium perfringens exotoxin

148.

staphylococcus aureus exotoxin mode of transmission

vehicle (food)

149.

staphylococcus aureus exotoxin virulence factors

heat-stable exotoxin

150.

staphylococcus aureus exotoxin culture/diagnosis

usually based on epidemiological evidence

151.

staphylococcus aureus exotoxin prevention

proper food handling

152.

staphylococcus aureus exotoxin treatment

supportive

153.

staphylococcus aureus exotoxin distinctive features

suspect in foods with high salt or sugar content

154.

staphylococcus aureus exotoxin epidemiological features

US: estimated 240,000 cases per year; category b bioterrorism agent

155.

bacillus cereus exotoxin mode of transmission

vehicle (food)

156.

bacillus cereus exotoxin virulence factors

heat-stable toxin, heat-liable toxin

157.

bacillus cereus exotoxin culture/diagnosis

microscopic analysis of food or stool

158.

bacillus cereus exotoxin prevention

proper food handling

159.

bacillus cereus exotoxin treatment

supportive

160.

bacillus cereus exotoxin distinctive features

two forms: emetic and diarrheal

161.

bacillus cereus exotoxin epidemiological features

US: estimated 63,000 cases per year

162.

clostridium perfringens exotoxin mode of transmission

vehicle (food)

163.

clostridium perfringens exotoxin virulence factors

heat-liable toxin

164.

clostridium perfringens exotoxin culture/diagnosis

detection of toxin in stool

165.

clostridium perfringens exotoxin prevention

proper food handling

166.

clostridium perfringens exotoxin treatment

supportive

167.

clostridium perfringens exotoxin distinctive features

acute abdominal pain

168.

clostridium perfringens exotoxin epidemiological features

US: estimated 966,000 cases per year, category b bioterrorism agent

169.

clostridium perfringens exotoxin disease table

170.

bacillus cereus exotoxin disease table

171.

staphylococcus aureus exotoxin disease table

172.

chronic disease causative agents

enteroaggregative E.coli (EAEC), cyclospora cayetanensis, giardia lamblia, entamoeba histolytica

173.

enteroaggregative E.coli (EAEC) mode of transmission

vehicle (food, water), fecal-oral

174.

enteroaggregative E.coli (EAEC) virulence factors

?

175.

enteroaggregative E.coli (EAEC)

difficult to distinguish from other E. coli

176.

enteroaggregative E.coli (EAEC) treatment

rehydration of ciprofioxacin

177.

enteroaggregative E.coli (EAEC) blood in stool

sometimes, mucus also

178.

enteroaggregative E.coli (EAEC) fever present

no

179.

enteroaggregative E.coli (EAEC) distinctive features

chronic in the malnourished

180.

enteroaggregative E.coli (EAEC) epidemiological features

developing countries: 87% of chronic diarrhea in children >2 years old

181.

cyclospora cayetanensis mode of transmission

fecal-oral, vehicle

182.

cyclospora cayetanensis virulence factors

invasiveness

183.

cyclospora cayetanensis culture/diagnosis

stool examination, PCR

184.

cyclospora cayetanensis prevention

washing, cooking food, and personal hygiene

185.

cyclospora cayetanensis treatment

TMP-SMZ

186.

cyclospora cayetanensis fever present

usually

187.

cyclospora cayetanensis blood in stool

no

188.

cyclospora cayetanensis distinctive features

N/A

189.

cyclospora cayetanensis epidemiological features

US: estimated 16,000 cases per year; internationally: endemic 27 countries, mostly tropical

190.

giardia lamblia mode of transmission

vehicle, fecal-oral, direct and indirect contact

191.

giardia lamblia virulence factors

attachment to intestines alters mucosa

192.

giardia lamblia culture/diagnosis

stool examination, ELISA

193.

giardia lamblia prevention

water hygiene, personal hygiene

194.

giardia lamblia treatment

tinidazole, nitazoxanide

195.

giardia lamblia fever present

not usually

196.

giardia lamblia blood in stool

no, mucus present (greasy and foul smelling)

197.

giardia lamblia distinctive features

frequently occurs in backpackers, campers

198.

giardia lamblia epidemiological features

US: estimated 1.2 million cases per year; internationally: prevalence rates from 2% to 5% in industrialized world

199.

entamoeba histolytica mode of transmission

vehicle, fecal-oral

200.

entamoeba histolytica virulence factors

lytic enzymes, induction of apoptosis, invasiveness

201.

entamoeba histolytica culture/diagnosis

PCR, stool examination, ELISA, serology

202.

entamoeba histolytica prevention

water hygiene, personal hygiene

203.

entamoeba histolytica treatment

metronidazole or paromomycin

204.

entamoeba histolytica fever present

yes

205.

entamoeba histolytica blood in stool

yes

206.

entamoeba histolytica distinctive features

N/A

207.

entamoeba histolytica epidemiological features

internationally: 40,000-100,000 deaths annually

208.

hepatitis A or E virus mode of transmission

fecal-oral, vehicle

209.

hepatitis A or E virus culture/diagnosis

IgM serology

210.

hepatitis A or E virus prevention

hepatitis a vaccine or combined; HAV/HBV vaccine

211.

hepatitis A or E virus treatment

HAV: hepatitis A vaccine or immune globulin; HEV: immune globulin

212.

hepatitis A or E virus incubation period

2-4 weeks

213.

hepatitis A or E virus epidemiological features

hepatitis A, US: 20,000 cases annually and 40% of adults show evidence of prior infection; internationally: 1.4 million cases per year; hepatitis E, internationally: 20 million infections per year; 60% in east and southeast asia

214.

hepatitis B virus mode of transmission

parenteral (blood contact), direct contact (especially sexual), vertical

215.

hepatitis B virus virulence factors

latency

216.

hepatitis B virus prevention

HMV recombinant vaccine

217.

hepatitis B virus culture/diagnosis

ELISA

218.

hepatitis B virus treatment

interferon, tenofovir, or entecavir

219.

hepatitis B virus incubation period

1-6 months

220.

hepatitis B virus epidemiological features

US: 19,000 new cases per year; 800,000 to 2.2 million have chronic infection internationally: 240 million

221.

hepatitis C virus mode of transmission

parenteral (blood contact), vertical

222.

hepatitis C virus virulence factors

core protein suppresses immune function

223.

hepatitis C virus culture/diagnosis

serology, also PCR

224.

hepatitis C virus prevention

N/A

225.

hepatitis C virus treatment

sofosbuvir + simeprevir

226.

hepatitis C virus incubation period

2-8 weeks

227.

hepatitis C virus epidemiological features

US: estimated 30,000 new diagnoses per year; internationally: 150 million chronically infected

228.

intestinal distress causative agents

enterobius vermicularis (pinworm), trichuris trichiura (whipworm), diphyllobothrium latum (fish tapeworm), hymenolepis nana and H. diminuta

229.

enterobius vermicularis (pinworm) disease table

230.

enterobius vermicularis (pinworm) modes of transmission

cycle A: vehicle (food, water), formites, self-inoculation

231.

enterobius vermicularis (pinworm) culture/diagnosis

adhesive tape + microscopy

232.

enterobius vermicularis (pinworm) prevention

hygiene

233.

enterobius vermicularis (pinworm) treatment

mebendazole, piperazine

234.

enterobius vermicularis (pinworm) distinctive features

common in the US

235.

enterobius vermicularis (pinworm) epidemiological features

US: up to 40 million cases per year

236.

trichuris trichiura (whipworm) disease table

237.

trichuris trichiura (whipworm) mode of transmission

cycle A: vehicle (soil), fecal-oral

238.

trichuris trichiura (whipworm) virulence factors

burrowing and invasiveness

239.

trichuris trichiura (whipworm) culture/diagnosis

blood count, serology, egg or worm detection

240.

trichuris trichiura (whipworm) prevention

hygiene, sanitation

241.

trichuris trichiura (whipworm) treatment

mebendazole

242.

trichuris trichiura (whipworm) distinctive features

humans sole host

243.

trichuris trichiura (whipworm) epidemiological features

US: prevalence approx 0.1% internationally: prevalence as high as 80% in southeast asia, africa, the caribbeam, and central and south america

244.

diphyllobothrium latum (fish tapeworm) disease table

245.

diphyllobothrium latum (fish tapeworm) mode of transmission

cycle C; vehicle (seafood)

246.

diphyllobothrium latum (fish tapeworm) virulence factors

vitamin B12 usage

247.

diphyllobothrium latum (fish tapeworm) culture/diagnosis

blood count, serology, egg or worm detection

248.

diphyllobothrium latum (fish tapeworm) prevention

cook meat

249.

diphyllobothrium latum (fish tapeworm) treatment

praziquantel

250.

diphyllobothrium latum (fish tapeworm) distinctive features

largest human tapeworm (up to 30ft long); anemia

251.

diphyllobothrium latum (fish tapeworm) epidemiological features

estimated 20 million infections worldwide

252.

hymenolepis nana and H. diminuta disease table

253.

hymenolepis nana and H. diminuta mode of transmission

cycle C; vehicle (ingesting insects), fecal-oral

254.

hymenolepis nana and H. diminuta virulence factors

N/A

255.

hymenolepis nana and H. diminuta culture/diagnosis

blood count, serology, egg or worm detection

256.

hymenolepis nana and H. diminuta prevention

hygienic environment

257.

hymenolepis nana and H. diminuta treatment

praziquantel

258.

hymenolepis nana and H. diminuta distinctive features

most common tapeworm infection

259.

hymenolepis nana and H. diminuta epidemiological features

US: prevalence approximately 0.4%; internationally: the single most prevalent tapeworm infection

260.

intestinal distress plus migratory symptoms causative agents

toxocara species, ascaris lumbricoides (intestinal roundworm), necator americanus and ancylostoma duodenale (hookworms)

261.

toxocara species disease table

cycle A; dog or cat feces

262.

toxocara species culture/diagnosis

blood count, serology, egg or worm detection

263.

toxocara species prevention

hygiene

264.

toxocara species treatment

albendazole

265.

toxocara species distinctive features

can cause migration symptoms or blindness

266.

toxocara species epidemiological features

nearly 100% of newborn puppies in the US are infected; 14% of people in the US have been infected; considered a neglected parasitic infection

267.

ascaris lumbricoides (intestinal roundworm)

268.

ascaris lumbricoides (intestinal roundworm) mode of transmission

cycle A: vehicle (soil/fecal-oral), formites, self-inoculation

269.

ascaris lumbricoides (intestinal roundworm) virulence factors

induction of hypersensitivity, adult worm migration, abdominal obstruction

270.

ascaris lumbricoides (intestinal roundworm) culture/diagnosis

blood count, serology, egg or worm detection

271.

ascaris lumbricoides (intestinal roundworm) prevention

hygiene

272.

ascaris lumbricoides (intestinal roundworm) treatment

albendazole

273.

ascaris lumbricoides (intestinal roundworm) distinctive features

most cases mild, unnoticed

274.

ascaris lumbricoides (intestinal roundworm) epidemiological features

internationally: up to 25% prevalence, 80,000-100,000 deaths per year

275.

necator americanus and ancylostoma duodenale (hookworms) disease table

276.

necator americanus and ancylostoma duodenale (hookworms) mode of transmission

cycle B: vehicle (soil), formite

277.

necator americanus and ancylostoma duodenale (hookworms) virulence factors

induction of hypersensitivity, adult worm migration, abdominal obstruction

278.

necator americanus and ancylostoma duodenale (hookworms) culture/diagnosis

blood count, serology, egg or worm detection

279.

necator americanus and ancylostoma duodenale (hookworms) prevention

sanitation

280.

necator americanus and ancylostoma duodenale (hookworms) treatment

albendazole

281.

necator americanus and ancylostoma duodenale (hookworms) distinctive features

penetrates skin, serious intestinal symptoms

282.

necator americanus and ancylostoma duodenale (hookworms) epidemiological features

US: widespread in southeast until early 1900s; internationally: 800 million infected

283.

cysticercosis disease table

284.

cysticercosis mode of transmission

cycle C: vehicle (pork), fecal-oral

285.

cysticercosis culture/diagnosis

blood count, serology, egg or worm detection

286.

cysticercosis prevention

cook meat, avoid pig feces

287.

cysticercosis treatment

praziquantel

288.

cysticercosis distinctive features

ingesting larvae embedded in pork leads to intestinal tapeworms: ingesting eggs (fecal-oral route) causes cysticercosis, larval cysts embedded in tissue of new host

289.

cysticercosis epidemiological features

US: considered a neglected parasitic infection, common cause of seizures; internationally: very common in latin america and asia

290.

liver and intestinal disease table

291.

liver and intestinal causative agents

opisthorchis sinesis, clonorchis sinesis, and fasciola hepatica

292.

opisthorchis sinesis, clonorchis sinesis mode of transmission

cycle D: vehicle (fish or crustaceans)

293.

opisthorchis sinesis, clonorchis sinesis culture/diagnosis

blood count, serology, egg or worm detection

294.

opisthorchis sinesis, clonorchis sinesis prevention

cook food, sanitation of water

295.

opisthorchis sinesis, clonorchis sinesis treatment

praziquantel

296.

opisthorchis sinesis, clonorchis sinesis distinctive features

live in liver

297.

fasciola hepatica mode of transmission

cycle D: vehicle (water and water plants)

298.

fasciola hepatica culture/diagnosis

blood count, serology, egg or worm detection

299.

fasciola hepatica prevention

sanitation of water

300.

fasciola hepatica treatment

triclabendcazole

301.

fasciola hepatica distinctive features

live in liver and gallbladder

302.

muscle and neurological symptoms disease table

303.

muscle and neurological symptoms causative agents

trichinella species

304.

muscle and neurological symptoms culture/diagnosis

serology combined with clinical picture; muscle biopsy

305.

muscle and neurological symptoms prevention

cook meat

306.

muscle and neurological symptoms treatment

mebendazole, steroids

307.

muscle and neurological symptoms distinctive features

brain and heart involvement can be fatal

308.

muscle and neurological symptoms epidemiological features

US: 20 cases per year; internationally: 10,000 cases per year

309.

schistosomiasis liver disease table

310.

schistosomiasis causative agent

schistosoma mansoni, S. japonicum

311.

schistosomiasis mode of transmission

cycle D: vehicle (contaminated water)

312.

schistosomiasis virulence factors

antigenic "cloaking"

313.

schistosomiasis culture/diagnosis

identification of eggs in feces, scarring of intestines detected by endoscopy

314.

schistosomiasis prevention

avoiding contaminated vehicles

315.

schistosomiasis treatment

praziquantel

316.

schistosomiasis distinctive features

penetrates skin, lodges in blood vessels of intestine, damages liver

317.

schistosomiasis epidemiological features

internationally: 230 million new infections per year by these and the urinary schistosome

318.

gram-positive, endospore-forming bacteria

clostridioides difficile (antibiotic-associated diarrhea), bacillus cereus (food poisoning), clostridium perfringens (food poisoning)

319.

gram-positive bacteria

streptococcus mutans (dental caries), streptococcus sobrinus (dental caries), staphylococcus aureus (food poisoning)

320.

gram-negative bacteria

periodontal disease, helicobacter pylori, salmonella, shigella, escherichia coli STEC, other E.coli, campylobacter jejuni, vibrio cholera, non-cholera vibrio species

321.

DNA viruses

hepatitus B virus

322.

RNA viruses

mumps, rotavirus, norovirus, hepatitis A, E, and C

323.

protozoa

cryptosporidium, cyclospora cayetanesis, giardia duodenalis, enatmoeba histolytica

324.

helminths-nematodes

enterobius vermicularis, trichuris trichiura, toxocara species, ascaris lumbricoides, necator americanus, ancylostoma duodenale, trichinella species

325.

helminths-cestodes

diphyllobothrium latum, hymenolepis nana, H. diminuta, taenia solium, opisthorchis sinensis, clonorchis sinensis

326.

helminths-trematodes

fasciola hepatica, schistosoma mansoni, S. japonicum